Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.

Journal of clinical pharmacology 20121201

Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.

The American journal of cardiology 20121101

Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.

Expert opinion on drug safety 20121101

Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways.

Life sciences 20121015

Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues.

Life sciences 20121015

Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.

Life sciences 20121015

The combination of theophylline and endothelin receptor antagonism improves exercise performance of rats under simulated high altitude.

Journal of applied physiology (Bethesda, Md. : 1985) 20121015

LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study.

Biomedical chromatography : BMC 20121001

Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.

Journal of the American College of Cardiology 20120703

Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.

Current medical research and opinion 20120601

Treatment of pulmonary arterial hypertension in connective tissue disease.

Drugs 20120528

Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120515

Chronic endothelin A receptor blockade attenuates contribution of sympathetic nervous system to salt hypertension development in adult but not in young Dahl rats.

Acta physiologica (Oxford, England) 20120501

Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics.

International journal of cardiology 20120419

Endothelin-1 promotes cytoplasmic accumulation of RIP140 through a ET(A)-PLCβ-PKCε pathway.

Molecular and cellular endocrinology 20120404

ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

Cardiovascular therapeutics 20120401

eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype.

Journal of the American Society of Nephrology : JASN 20120401

Rapid determination of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode.

Journal of separation science 20120401

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

The AAPS journal 20120301

Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.

Hypertension (Dallas, Tex. : 1979) 20120301

Synthesis of (+)-ambrisentan via chiral ketone-catalyzed asymmetric epoxidation.

The Journal of organic chemistry 20120106

Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

Chest 20120101

Inhaled treprostinil: a therapeutic review.

Drug design, development and therapy 20120101

Pulmonary arterial hypertension: advances in pathophysiology and management.

Indian journal of pharmacology 20120101

A novel expression of exercise induced pulmonary hypertension in human immunodeficiency virus patients: a pilot study.

The open cardiovascular medicine journal 20120101

Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.

Journal of medical economics 20120101

Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension.

PloS one 20120101

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

PloS one 20120101

Pulmonary arterial hypertension: an update.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20111201

[Treatment of pulmonary fibrosis. New substances and new interventions].

Der Internist 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience.

Postgraduate medicine 20111101

Macitentan: entry-into-humans study with a new endothelin receptor antagonist.

European journal of clinical pharmacology 20111001

Endothelin receptor antagonists -- their role in pulmonary medicine.

Revue des maladies respiratoires 20111001

Ambrisentan for sarcoidosis associated pulmonary hypertension.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 20111001

Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.

Current medical research and opinion 20110901

Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.

Zeitschrift fur Gastroenterologie 20110901

Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far.

Hematology reports 20110831

Ambrisentan.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20110801

Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.

The American journal of cardiology 20110715

Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.

Expert opinion on pharmacotherapy 20110701

Synthesis and in vitro evaluation of ambrisentan analogues as potential endothelin receptor antagonists.

Bioorganic & medicinal chemistry letters 20110701

[Treatment of idiopathic pulmonary arterial hypertension].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20110701

Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.

European journal of pharmacology 20110625

New perspectives for the treatment of pulmonary hypertension.

British journal of pharmacology 20110501

Novel therapeutic approaches for pulmonary fibrosis.

British journal of pharmacology 20110501

Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.

The American journal of cardiology 20110501

With REMS, what goes up can come down.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110501

Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension.

Angiogenesis 20110301

Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.

Internal medicine journal 20110301

Pharmacokinetic evaluation of ambrisentan.

Expert opinion on drug metabolism & toxicology 20110301

Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.

Journal of gastrointestinal and liver diseases : JGLD 20110301

[Changes long term prognosis of 17 patients with pulmonary artery hypertension].

Revista medica de Chile 20110301

Endothelin receptor antagonists as disease modifiers in systemic sclerosis.

Inflammation & allergy drug targets 20110201

Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers.

Journal of clinical pharmacology 20110101

Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension.

Chest 20110101

Identification of clinically used drugs that activate pregnane X receptors.

Drug metabolism and disposition: the biological fate of chemicals 20110101

Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.

PharmacoEconomics 20110101

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.

Vascular health and risk management 20110101

Pulmonary vascular complications of chronic liver disease: Pathophysiology, imaging, and treatment.

Annals of thoracic medicine 20110101

Short term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomised controlled trial.

BMC pulmonary medicine 20110101

[Pulmonary arterial hypertension: changing approaches to management].

Kardiologiia 20110101

Recent trends in pulmonary arterial hypertension.

Lung India : official organ of Indian Chest Society 20110101

Therapeutic strategies in pulmonary hypertension.

Frontiers in pharmacology 20110101

Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice.

Arthritis research & therapy 20110101

Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

Orphanet journal of rare diseases 20110101

Diagnosis and management of pulmonary arterial hypertension.

Pulmonary medicine 20110101

Anaesthesia Management of Caesarean Section in Two Patients with Eisenmenger's Syndrome.

Anesthesiology research and practice 20110101

Diagnostic and therapeutic algorithm for pulmonary arterial hypertension.

Pulmonary circulation 20110101

Overview of current therapeutic approaches for pulmonary hypertension.

Pulmonary circulation 20110101

Vascular involvement in systemic sclerosis (scleroderma).

Journal of inflammation research 20110101

Assessment of daily life physical activities in pulmonary arterial hypertension.

PloS one 20110101

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.

International journal of rheumatology 20110101

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.

BMC pulmonary medicine 20110101

Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.

Pulmonary medicine 20110101

Surgical treatment of pulmonary hypertension: Lung transplantation.

Pulmonary circulation 20110101

Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management.

European respiratory review : an official journal of the European Respiratory Society 20101201

The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results.

Current cardiology reviews 20101101

Potential for pharmacokinetic interactions between ambrisentan and cyclosporine.

Clinical pharmacology and therapeutics 20101001

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses.

European heart journal 20100901

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.

Canadian journal of physiology and pharmacology 20100601

Combined vasomodulatory therapy for severe pulmonary hypertension in chronic hypersensitivity pneumonitis.

Medical science monitor : international medical journal of experimental and clinical research 20100501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100501

[Pulmonary circulation: contributions of the year 2009].

Archivos de bronconeumologia 20100301

Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.

Journal of cardiac failure 20100201

[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].

Revue des maladies respiratoires 20100201

Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.

Respiratory research 20100101

Pulmonary arterial hypertension in connective tissue diseases.

Cardiology in review 20100101

Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

BMC cardiovascular disorders 20100101

Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.

Applied health economics and health policy 20100101

Portopulmonary hypertension.

Annals of thoracic medicine 20100101

Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study.

Clinical drug investigation 20100101

Pharmacotherapeutic management of pulmonary arterial hypertension.

Cardiology in review 20100101

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.

Vascular health and risk management 20100101

Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.

Drug design, development and therapy 20100101

Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan.

Therapeutics and clinical risk management 20100101

Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.

Clinical drug investigation 20100101

Inhaled treprostinil and pulmonary arterial hypertension.

Vascular health and risk management 20100101

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy.

Drug, healthcare and patient safety 20100101

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

Journal of pharmaceutical sciences 20091201

Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.

British journal of haematology 20091201

[Endothelin receptor antagonists - their role in pulmonary medicine].

Revue des maladies respiratoires 20091201

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.

Journal of the American College of Cardiology 20091117

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20091101

Can we improve outcome of congenital diaphragmatic hernia?

Pediatric surgery international 20090901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090901

Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.

Expert opinion on pharmacotherapy 20090801

Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension.

Korean circulation journal 20090801

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

Journal of clinical pharmacology 20090601

Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.

Rheumatology (Oxford, England) 20090601

Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.

IDrugs : the investigational drugs journal 20090601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090601

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.

British journal of clinical pharmacology 20090501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090401

Ambrisentan: new drug. Too risky in mildly symptomatic pulmonary hypertension.

Prescrire international 20090401

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.

European heart journal 20090201

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

Chest 20090101

[Pulmonary arterial hypertension: a voyage around the year 2008].

Archivos de bronconeumologia 20090101

Pulmonary arterial hypertension in children: a medical update.

Indian journal of pediatrics 20090101

Review of inhaled iloprost for the control of pulmonary artery hypertension in children.

Vascular health and risk management 20090101

New concepts in the invasive and non invasive evaluation of remodelling of the right ventricle and pulmonary vasculature in pulmonary arterial hypertension.

The open respiratory medicine journal 20090101

Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer.

Oncology research 20090101

Treatment of pediatric pulmonary hypertension.

Vascular health and risk management 20090101

Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.

Applied health economics and health policy 20090101

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.

Vascular health and risk management 20090101

Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model.

Clinical drug investigation 20090101

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

Drug design, development and therapy 20090101

Therapeutic methods used in patients with Eisenmenger syndrome.

Cardiology journal 20090101

Integrated care and optimal management of pulmonary arterial hypertension.

Journal of multidisciplinary healthcare 20090101

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.

Journal of clinical pharmacology 20081201

Ambrisentan and its role in the management of pulmonary arterial hypertension.

Drugs of today (Barcelona, Spain : 1998) 20081201

Role of ambrisentan in the management of pulmonary hypertension.

The Annals of pharmacotherapy 20081101

[Specific drugs for the treatment of pulmonary arterial hypertension - current status].

Deutsche medizinische Wochenschrift (1946) 20081001

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

Vascular health and risk management 20081001

Pulmonary arterial hypertension: on the way to a manageable disease.

Current opinion in investigational drugs (London, England : 2000) 20080901

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

European heart journal 20080801

[Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20080801

The management of pulmonary hypertension in children.

Archives of disease in childhood 20080701

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

Circulation 20080610

The status of pulmonary arterial hypertension in 2008.

Circulation 20080610

[Systemic sclerosis].

Medizinische Monatsschrift fur Pharmazeuten 20080501

Ambrisentan for the management of pulmonary arterial hypertension.

Clinical therapeutics 20080501

[Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].

La Revue de medecine interne 20080401

The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

British journal of pharmacology 20080301

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080301

Endothelin receptor antagonists in pulmonary arterial hypertension.

The European respiratory journal 20080201

Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management.

Current cardiology reviews 20080201

Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20080101

Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension.

Scandinavian journal of clinical and laboratory investigation 20080101

Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.

Drugs 20080101

Ambrisentan.

Drugs 20080101

Pulmonary hypertension: past, present and future.

Annals of thoracic medicine 20080101

Ambrisentan for the treatment of pulmonary arterial hypertension.

Drug design, development and therapy 20080101

Review of bosentan in the management of pulmonary arterial hypertension.

Vascular health and risk management 20071201

Ambrisentan (Letairis) for pulmonary arterial hypertension.

The Medical letter on drugs and therapeutics 20071022

Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension.

International journal of clinical practice 20071001

Expert opinion on available options treating pulmonary arterial hypertension.

Expert opinion on pharmacotherapy 20071001

Ambrisentan.

Nature reviews. Drug discovery 20070901

Therapeutic challenges for systemic sclerosis: facts and future targets.

Annals of the New York Academy of Sciences 20070901

New drug approved for pulmonary arterial hypertension.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070801

EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils.

Brain research 20070709

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070401

Pathophysiological role of platelets in acute experimental pancreatitis: influence of endothelin A receptor blockade.

Cell and tissue research 20070301

Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.

Clinics in chest medicine 20070301

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070301

A review of pulmonary arterial hypertension: role of ambrisentan.

Vascular health and risk management 20070201

Therapeutic targets in systemic sclerosis.

Arthritis research & therapy 20070101

New drugs: ambrisentan, temsirolimus, and eculizumab.

Journal of the American Pharmacists Association : JAPhA 20070101

[Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].

Kardiologiia 20070101

Management of pulmonary arterial hypertension associated with congenital heart disease.

Romanian journal of internal medicine = Revue roumaine de medecine interne 20070101

Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.

Core evidence 20070101

[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].

Deutsche medizinische Wochenschrift (1946) 20061208

Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?

Current medical research and opinion 20061201

Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.

Proceedings of the American Thoracic Society 20060901

Endothelin receptor antagonists.

Pharmacology & therapeutics 20060601

Profile of past and current clinical trials involving endothelin receptor antagonists: the novel '-sentan' class of drug.

Experimental biology and medicine (Maywood, N.J.) 20060601

Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin.

Experimental biology and medicine (Maywood, N.J.) 20060601

Attenuation of proinflammatory gene expression and microcirculatory disturbances by endothelin A receptor blockade after orthotopic liver transplantation in pigs.

Surgery 20060101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060101

Ambrisentan, a non-peptide endothelin receptor antagonist.

Cardiovascular drug reviews 20060101

Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.

Nature clinical practice. Rheumatology 20051201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20051001

Ambrisentan therapy for pulmonary arterial hypertension.

Journal of the American College of Cardiology 20050802

Ambrisentan for pulmonary arterial hypertension.

Future cardiology 20050701

[Emerging therapies for the treatment of pulmonary arterial hypertension].

Herz 20050601

[Treatment algorithm for pulmonary arterial hypertension].

Herz 20050601

Improvement of postischemic hepatic microcirculation after endothelinA receptor blockade--endothelin antagonism influences platelet-endothelium interactions.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20050201

Drug treatment of pulmonary arterial hypertension: current and future agents.

Drugs 20050101

Effects of ET(A) receptor antagonism on proinflammatory gene expression and microcirculation following hepatic ischemia/reperfusion.

Microcirculation (New York, N.Y. : 1994) 20050101

Changes of vasoregulatory gene expression following hepatic ischemia/reperfusion and treatment with endothelin-A receptor blockade.

Journal of cardiovascular pharmacology 20041101

Endothelin-A receptor blockade improves postischemic hepatic microhemodynamics.

Journal of cardiovascular pharmacology 20041101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20041001

Endothelin receptor antagonists in pulmonary arterial hypertension.

Journal of the American College of Cardiology 20040616

Endothelin receptor antagonists are not beneficial in the therapy of acute experimental pancreatitis.

Langenbeck's archives of surgery 20040601

Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.

Journal of medicinal chemistry 20040520

Influence of a selective endothelin(A) receptor antagonist on the quantitative mRNA expression and the immunohistochemistry of vasoactive mediators after pancreas transplantation.

Transplantation proceedings 20030901

Cerebrovascular characterization of the novel nonpeptide endothelin-A receptor antagonist LU 208075.

Clinical neuropharmacology 20030101

Ambrisentan (Myogen).

Current opinion in investigational drugs (London, England : 2000) 20021001

Administration of a selective endothelin-a receptor antagonist (BSF 208075) improves hepatic warm ischemia/reperfusion injury in pigs.

Transplantation proceedings 20020901

Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery.

Clinical science (London, England : 1979) 20020801

Endothelin A-receptor blockade in experimental diabetes improves glucose balance and gastrointestinal function.

Clinical science (London, England : 1979) 20020801